PTC that develops in patients with acromegaly may have a different prognosis or be treated with a different modality, because a hyperactive GH-IGF-1 axis may play a dominant role in development of PTC rather than the BRAFV600E mutation. The gene discussed is GH1; the disease is acromegaly.